Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.77 |
| ▸ | VDR | P11473 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.77 |
| ▸ | CDC25A | P30304 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | PGR | P06401 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 1/20 | 0.77 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1650555 | 1.00 | MAPT (0.77) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL22141545 | 1.00 | MAPT (0.77) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL23619148 | 1.00 | MAPT (0.77) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL23619143 | 0.88 | VDR (0.61) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL1140731 | 0.88 | VDR (0.67) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL1140730 | 0.88 | VDR (0.67) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL21264751 | 0.88 | MAPT (0.80) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL21128778 | 0.88 | MAPT (0.80) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL12372105 | 0.88 | MAPT (0.80) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL11977559 | 0.88 | MAPT (0.80) | MAPTVDRMEN1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0753510-B1 | Method of production of 9,10-secocholesta-5,7,10(19)-trienes | CERBIOS PHARMA SA (CH) | 1998-10-21 | — | — | EP | claimed |
| US-5698714-A | Process for the preparation of 9, 10-secocholesta-5,7,10 (19)-trienes | CERBIOS PHARMA S.A. (CH) | 1997-12-16 | — | — | US | claimed |
| EP-0753510-A1 | Method of production of 9,10-secocholesta-5,7,10(19)-trienes | Cerbios-Pharma S.A. (CH) | 1997-01-15 | — | — | EP | claimed |
| EP-0377743-B1 | STEROID COMPOUNDS | KURARAY CO (JP) | 1995-06-28 | — | — | EP | claimed |
| EP-0377743-A1 | STEROID COMPOUNDS | KURARAY CO., LTD. (JP) | 1990-07-18 | — | — | EP | claimed |
| CN-113462605-B | Pediococcus pentosaceus368 microbial inoculum and preparation method and application thereof | 云南省畜牧兽医科学院 | 2023-03-21 | — | — | CN | disclosed |
| US-20120258938-A1 | Enzymatic Production or Chemical Synthesis and Uses for 5,7-Dienes and UVB Conversion Products Thereof | SLOMINSKI ANDREJ (US) | 2012-10-11 | — | — | US | disclosed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| US-7019146-B1 | Ferrocene compound and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISYA (JP) | 2006-03-28 | — | — | US | disclosed |
| EP-1533316-A1 | FERROCENE COMPOUND AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20050084908-A1 | Methods for detecting binding of low-molecular-weight compound and its binding partner molecule | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2005-04-21 | — | — | US | disclosed |
| US-20040248859-A1 | Medicinal compositions for treating secondary parathyroid hyperfunction and remedies for cardiovascular complications in association with treatment for secondary parathyroid hyperfunction | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-12-09 | — | — | US | disclosed |
| US-5698714-A | Process for the preparation of 9, 10-secocholesta-5,7,10 (19)-trienes | CERBIOS PHARMA S.A. (CH) | 1997-12-16 | — | — | US | disclosed |
| EP-0753510-A1 | Method of production of 9,10-secocholesta-5,7,10(19)-trienes | Cerbios-Pharma S.A. (CH) | 1997-01-15 | — | — | EP | disclosed |
| EP-0753510-A1 | Method of production of 9,10-secocholesta-5,7,10(19)-trienes | Cerbios-Pharma S.A. (CH) | 1997-01-15 | — | — | EP | disclosed |
| EP-0753510-A1 | Method of production of 9,10-secocholesta-5,7,10(19)-trienes | Cerbios-Pharma S.A. (CH) | 1997-01-15 | — | — | EP | disclosed |
| EP-0377743-B1 | STEROID COMPOUNDS | KURARAY CO (JP) | 1995-06-28 | — | — | EP | disclosed |
| US-5218109-A | STEROID COMPOUNDS | KURARAY CO., LTD. (JP) | 1993-06-08 | — | — | US | disclosed |
| EP-0377743-A1 | STEROID COMPOUNDS | KURARAY CO., LTD. (JP) | 1990-07-18 | — | — | EP | disclosed |
| US-RE30538-E | VITAMIN D3 DERIVATIVE WHICH PROMOTES INTESTINAL CALCIUM TRANSPORT AND BONE CALCIUM MOBILIZATION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | MAPT 4587/4885VDR 547/4885MEN1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.